HOME
SEARCH
RSS FEED
SUBSCRIBE
Minibody for Conditioning prior to Hematopoietic Stem Cell and Progenitor Cell Transplantation
Case ID:
TAB-3812
Web Published:
12/6/2022
Description:
Patient conditioning is a critical initial step in hematopoietic stem and progenitor cell (HSPC) transplantation procedures to enable marrow engraftment of infused cells. Conditioning regimens have traditionally been achieved by delivering cytotoxic doses of chemotherapeutic agents and radiation. However, these regimens are associated with significant morbidity and mortality, and cannot be used safely in elderly or subjects with comorbidities. Scientists at the National Heart, Lung, and Blood Institute (NHLBI), the University of Massachusetts Medical School (UMMS), and the University of Colorado (CU) have developed a recombinant bivalent (bi) single-chain variable fragment (scFV) minibody targeting the cMPL receptor on HSPCs, fused with diphtheria toxin (DT) truncated at residue 390 (DT390-biscFV(cMPL)) that can be used to deplete HSPCs with increased safety in patients undergoing HSPC transplantation.
Patent Information:
Title
App Type
Country
Serial No.
Patent No.
File Date
Issued Date
Expire Date
Patent Status
Direct Link:
https://nih.technologypublisher.com/tech/Minibody_for_Conditioning_prior_to_H ematopoietic_Stem_Cell_and_Progenitor_Cell_Transplantation
Category(s):
Ophthalmology
Endocrinology
Dental
Oncology
Cardiology
Consumer Products
Therapeutics
Infectious Disease
Immunology
Antibodies
Bookmark this page
Download as PDF
For Information, Contact:
Vincent Kolesnitchenko
Technology Development Specialist
NIH Technology Transfer
301-594-4115
vk5q@nih.gov
Inventors:
Daisuke Araki
Diogo Magnani
Zhirui Wang
Andre Larochelle
Keywords:
1CXXXX
2IXXXX
2JXXXX
Anti-cMPL
Cells
DEPLETION
Divalent
DT-390-Conjugated
hematopoietic
Progenitor
ScFv
Stem
VCXXXX
VPXXXX
WJXXXX
WMXXXX
XAXXXX
Home
|
Search
|
RSS
|
Subscribe
© 2024. All Rights Reserved. Powered by
Inteum